



Dear Geneos stakeholders and well-wishers,

We trust that like us, you emerged from 2020 safe and more resilient. We are looking forward to 2021 and a new normal. While the whole world (Geneos included) was rightly focused on the huge personal and business disruptions caused by the SARS-CoV-2 pandemic and mitigating their effects, Geneos quietly went about its second year in operation. Geneos Therapeutics turns 2 on Feb 21, 2021. This has been a year of operationalizing the company's clinical programs and setting up the company for the key clinical proof-of-concept data to become available in 2021. The Geneos team has a lot to celebrate. In this second year, we:

- **Initiated the GT-30 clinical trial for our lead program treating patients with advanced hepatocellular carcinoma.** We built out our pipeline to cover three solid tumor programs:
 - GT-10: Anaplastic astrocytoma (Compassionate use IND to treat a single patient)
 - GT-20: Newly diagnosed GBM
 - GT-30: Advanced hepatocellular carcinoma
- **Treated the first patients in the GT-20 and GT-30 studies** with their own tumor specific personalized immunotherapy demonstrating manufacturability of the patient specific products, safety and feasibility of the GT-EPIC™ platform for cancer treatment.
- **Demonstrated proof-of-concept immune responses and clinical signals in humans.** We demonstrated that patients treated with their GT-EPIC™ based neoantigen immunotherapies:
 - Induce CD4 and CD8 T cell responses to the vast majority of the encoded neoantigens
 - Target as many as 40 tumor-specific neoantigens at a time
 - Receive their patient-specific treatments within 6-8 weeks of a biopsy sample

These three demonstrable criteria represent the key pillars of differentiation between the Geneos treatments and a number of other approaches being pursued for cancer neoantigen vaccines.

Geneos continues to operate as a lean and highly experienced, yet nimble, team. The company's footprint has remained stable through the year allowing us to rapidly respond to the many Covid-19 related contingencies we had to face. The clinical team led by Joann Peters – VP, Clinical and Corporate Operations and Dr. Alfredo Perales-Puchalt – VP, R&D and their team members Sarah Rochestie, Neil Cooch, and Elizabeth Skale deserve all the credit for the efficient clinical execution. The team is well supported by our expert consultant and advisory team of Dr. Beth Junker – Manufacturing, CMC; Dr. Ildiko Csiki – Oncology clinical development; and Ms. Federica O'Brien (Genova Group, Finance and Accounting); as well as our manufacturing partner (VGXI, Inc.) and multiple contract clinical and regulatory partner companies.

The GT-EPIC platform is established and running efficiently. Looking ahead, I see 2021 as the year of clinical expansion. Based on our early clinical data we took the decision to expand enrollment in our GT-30 study from 12 to 24 patients and thereby potentially demonstrate significant improvements over the standard of care. In 2021, we expect to report clinical safety and neoantigen targeted immune response data on all three clinical programs as well as clinical efficacy data (ORR, PFS, and OS) from the GT-30 program. In parallel, we shored up our balance sheet to support these programs and continuing operations via our Series A1 financing which we expect to close in early 2021. The versatile GT-EPIC™ platform sets up the company well to build on its initial success and grow/expand into additional cancer indications and treatment modalities in the personalized medicine space.

In closing, let us remind ourselves that Our vision is to treat cancer one patient at a time with treatments that are specific to and based on each person's tumor. Why? Because each patient's tumor is different.

We are thankful to our network of support. We would not be where we are without the support and shared vision of our investors, partners, advisors, and academic/clinical collaborators in enabling us to make rapid progress on our mission.

I am pleased to enclose our updated corporate presentation for Q1-2021. More details on the GT-EPIC™ platform and our programs can be found at: www.geneostx.com

Upwards and onwards to an exciting 2021!

A handwritten signature in black ink, appearing to read "N. Sardesai". The signature is fluid and cursive, with a large initial "N" and "S".

Niranjan Y. Sardesai, Ph.D.
Founder, President & CEO

E-mail: sardesai@geneostx.com